To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

NCT03610880 | Completed Phase 1

• 1 other identifier: TGDAG-C-1
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the drug-drug reactions between TG-2349 and DAG181, and the pharmacokinetics and tolerability profile in healthy Chinese volunteers to be the reference for protocol designs of subsequent clinical trials.

Conditions

Healthy Chinese Volunteers

Keywords

healthy Chinese volunteers; TG-2349; DAG181; pharmacokinetics; safety; multiple ascending oral doses

Outcome Measures

Primary Outcomes (3)

• Cmax(ss)

  Maximum Plasma Concentration in a stable state

  14 weeks

• Ctrough(ss)

  Trough Plasma Concentration in a stable state

  14 weeks

• AUC(0-τ, ss)

  Area Under the Plasma Concentration vs. Time Curve

  14 weeks

Secondary Outcomes (25)

• Cmax

  14 weeks

• Ctrough

  14 weeks

• Tmax

  14 weeks

• AUC(0-24)

  14 weeks

• Tmax(ss)

  14 weeks

Study Arms (2)

TG-2349 (400 mg) plus DAG181 (200 mg)

EXPERIMENTAL

Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181

Drug: TG-2349 (400 mg) plus DAG181 (200 mg)

DAG181 (200 mg) plus TG-2349 (400 mg)

EXPERIMENTAL

Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181

Drug: DAG181 (200 mg) plus TG-2349 (400 mg)

Interventions

TG-2349 (400 mg) plus DAG181 (200 mg) DRUG

Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg

TG-2349 (400 mg) plus DAG181 (200 mg)

DAG181 (200 mg) plus TG-2349 (400 mg) DRUG

Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg

DAG181 (200 mg) plus TG-2349 (400 mg)

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Before starting the study, an informed consent form (ICF) approved by the Institute Review Board (IRB) is obtained from the subject or his/her legal representative；
• Male or female, and 18 to 45 years of age inclusive when signing ICF；
• Body mass index (BMI) in the range of 19.0 to 24.0 kg/m2 inclusive and male body weight ≥ 50 kg, female body weight ≥ 45 kg；
• In general good physical and mental health status on basis of medical history review, physical examination and vital signs, 12-lead ECG, and laboratory results at screening；
• For females, one of the following criteria must be fulfilled: (a) Had undergone surgical sterilization, or (b) Subjects of childbearing potential must satisfy the following criteria: Before group assignment, the urine pregnancy test is negative, and Subjects agree to use an approved contraceptive method (i.e. oral spermicidal agent, condoms, or intrauterine devices) during the entire study period (from Visit1 to Visit 2). Subject must also consent to keep the contraceptive method until 1 month after the study, and Breastfeeding is prohibited；
• Male must be willing to use a reliable form of contraception (use of a condom or spouses using any of the above standards) during the entire study period (from Visit1 to Visit 2) and within 1 month after the study；
• Have not used tobacco or nicotine-containing products within 1 month period to first dose of study drug；
• Willing to abstain from caffeine- or xanthine-containing beverages, including coffee and tea, chocolate, alcohol, grapefruit juice, and Seville oranges juice before 24 hr and during the Stay-on Site period.

You may not qualify if:

• Current, prior history, or family history of any disease of sudden cardiac death, myocardial ischemia, myocardial infarction, congestive heart failure, QT prolongation syndrome, hypokalemia, myocarditis, exertional dyspnea, cerebrovascular injury, venous thromboembolism；
• Requires concomitant medication associated with increased QTc interval (i.e. Class I or III antiarrhythmic agents, refer to appendix 1) or with cardiac insufficiency；
• Any abnormality on 12-lead ECG: PR\>240 ms, PR\<110 ms, QRS\>110 ms, QTc\>450 ms, or bradycardia ( heart rate \< 50 beats/min) at screening or the day -1；
• Any clinical significant abnormality on 12-lead ECG (i.e. atrioventricular block, TdT, other types of ventricular tachycardia, atrial fibrillation and ventricular flutter, clinical significant abnormality on T wave changes or any abnormality on 12-lead ECG that effects QTc intervals) at screening or the day -1；
• Systolic pressure \>140 mmHg or \<90 mmHg, diastolic pressure \>90 mmHg, pulse \<50 beats/min or \>100 beats/min at screening or the day -1；筛选或研究第-1天时收缩压\>140 mmHg或\<90 mmHg、舒张压\>90 mmHg、脉搏\<50次/分或\>100次/分；
• Any clinical significant abnormality on chest X-rays or abdominal ultrasound scan at screening (or within 2 weeks of signing the ICF)；
• Positive serological test for hepatitis A (IgM anti-HAV), hepatitis B (HbsAg), hepatitis C (anti-HCV antibody), or syphilis at screening；
• Pregnant or breastfeeding；
• Any abnormal laboratory values (normal value ±10％) that are considered clinical significant by the Investigator at screening or the day -1；
• Positive breath alcohol test or urine drug screen at screening or the day -1；
• Current or prior history of any disease of diabetes, cardiovascular, hepatic or renal impairment；
• Any dysphagia, malabsorption syndrome, or other gastrointestinal disturbances affecting drug absorption；
• Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy；
• History of epileptic seizure, mental disorders affecting the subject's compliance with the protocol, suicidal risk, or a history of alcohol or illicit drug abuse；
• Currently has any disease that seriously affects the immune system, for instance, human immunodeficiency virus (HIV) infection, hematological malignancy, solid cancer or splenectomy；

Sponsors & Collaborators

• Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.: lead
• R&G Pharma Studies Co.,Ltd.: collaborator

Study Sites (1)

Xiangya Hospital Central South University

Changsha, Hunan, China

Location

MeSH Terms

Interventions

yimitasvir

Study Officials

• Pingsheng Xu

  Xiangya Hospital of Central South University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: randomized, open-label, two-arm, parallel design

Study Record Dates

• First Submitted: May 24, 2018
• First Posted: August 1, 2018
• Study Start: October 17, 2017
• Primary Completion: February 5, 2018
• Study Completion: February 5, 2018
• Last Updated: August 1, 2018

Record last verified: 2018-07

Locations

CN (1)